I-Mab Stock Price, News & Analysis

I-Mab (Nasdaq: IMAB) announced two poster presentations showcasing data on lemzoparlimab at the 64th ASH Annual Meeting from December 10-13, 2022, in New Orleans. The presentations will cover biomarker analyses from a phase 2 study involving lemzoparlimab and azacitidine for myelodysplastic syndrome and preclinical data on leveraging CD47 and CD38 immuno-oncology targets for multiple myeloma treatment. The research indicates potential clinical benefits and therapeutic mechanisms, especially in high-risk populations, underscoring I-Mab's commitment to advancing lemzoparlimab's clinical development.

I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company, announced new preclinical data for its assets lemzoparlimab and uliledlimab, to be presented at the 37th SITC Annual Meeting in Boston from November 8-12, 2022. The presentations will include enhanced activity against HER2 expressing tumors and novel immune modulatory mechanisms of uliledlimab. Abstracts will be available on the SITC website on November 7, 2022. I-Mab continues its commitment to developing innovative biologics for cancer therapies and has multiple ongoing clinical studies.

I-Mab (Nasdaq: IMAB) announced the successful completion of an End-of-Phase 2 meeting with China's National Medical Products Administration (NMPA), leading to approval for a Phase 3 trial of lemzoparlimab combined with azacitidine for higher-risk myelodysplastic syndrome (HR-MDS). The encouraging Phase 2 results, presented at ESMO Congress 2022, showed that the combination therapy was effective and safe. The company aims to submit a biologic license application in China following this trial.

I-Mab announced positive results from its Phase 2 clinical trial of lemzoparlimab combined with azacitidine (AZA) for treating higher-risk myelodysplastic syndrome (HR-MDS) at the ESMO Congress 2022. The overall response rate (ORR) was 86.7% for patients treated over 6 months, while the complete response (CR) rate reached 40%. Notably, lemzoparlimab did not require priming dosing and exhibited no unexpected safety signals. A Phase 3 trial is planned to further evaluate this promising combination therapy.

I-Mab announced that the Phase 2 clinical trial results of lemzoparlimab, in combination with azacitidine, will be presented at the ESMO Congress 2022 on September 10. This presentation will feature initial results regarding the drug's efficacy for patients with higher risk myelodysplastic syndrome (HR-MDS). Additionally, an investor conference call is scheduled for September 12 at 8:00 a.m. ET to discuss the data in detail.

I-Mab (Nasdaq: IMAB) announced significant clinical achievements and financial results for the first half of 2022. Key milestones include positive data for lemzoparlimab, uliledlimab, and TJ-CD4B, with lemzoparlimab on track for a Phase 3 study targeting MDS. The partnership with AbbVie could yield up to $1.295 billion in milestone payments. With a robust cash position of $586 million, I-Mab is well-positioned to fund operations for over three years. The company plans to submit three BLAs by 2024, focusing on five key assets that drive its business strategy towards commercialization.

I-Mab (Nasdaq: IMAB) announced on August 23, 2022, its plan to implement a share repurchase program authorized by its Board of Directors. The Company and senior management, including Chairman Dr. Jingwu Zang, intend to use personal funds to buy up to US$40 million of the Company's American Depositary Shares (ADSs) on the open market. The timing and amount of repurchases will comply with U.S. Securities and Exchange Commission regulations. This move aims to enhance shareholder value as I-Mab progresses in its mission to develop innovative biologics for immuno-oncology diseases.

I-Mab, a clinical-stage biopharmaceutical company, will report its business and financial results for the six months ending June 30, 2022, on August 30, 2022. The updates will cover global clinical development of key assets, upcoming milestones, and potential share purchase programs. Conference calls are scheduled on the same day, at 7:00 a.m. ET for Mandarin and 8:15 a.m. ET for English. I-Mab aims to deliver innovative biologics for immuno-oncology diseases and has over 20 clinical and preclinical-stage drug candidates in its pipeline.

I-Mab (Nasdaq: IMAB) has initiated a Phase 1 clinical trial for TJ-CD4B, a novel Claudin 18.2 x 4-1BB bispecific antibody targeting solid tumors, such as gastric and pancreatic cancers, with the first patient treated in China. The FDA granted Orphan Drug Designation for this therapy in March 2022, signifying its potential for treating gastric cancer. Experts suggest TJ-CD4B could offer more effective treatment options compared to existing therapies, reflecting I-Mab's commitment to developing innovative cancer therapies.